Type2 Diabetes Clinical Trial
Official title:
The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients
The population of type 2 diabetes increased enormously worldwide. As disease progression, uncontrolled type 2 diabetes patients need multiple daily insulin injections, but the risk of body weight gain and hypoglycemia will increase. In recent years, the newly oral anti-hypoglycemic agents developed, such as dipeptidyl peptidase-4 inhibitors (DPP4i) and sodium-glucose co-transporter 2 inhibitors (SGLT2i). The former indirectly stimulate insulin secretion and suppress glucagon through increase incretin. The later inhibit re-absorption of blood glucose in proximal renal tubule to improve hyperglycemia. According to the guideline published in 2017 by American diabetes Associations, if patients received premix insulin injections twice daily and their glycemic control can't meet the target, increase the frequency of injection such as basal bolus would be considered. However, it is difficult for some patients and it may cause more hypoglycemia and gain of body weight. Because previous report revealed dipeptidyl peptidase-4 inhibitors or sodium-glucose co-transporter 2 inhibitors added to insulin resulted in better glycemic control, but there was no direct comparison, so we design this study to observe the efficacy of these two drugs in uncontrolled diabetes patient received twice daily insulin injections.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03239366 -
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
|
Phase 2 | |
| Completed |
NCT04597229 -
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
|
N/A | |
| Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
| Active, not recruiting |
NCT04599920 -
Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)
|
N/A | |
| Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
| Completed |
NCT04382521 -
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
|
N/A | |
| Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
| Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
| Completed |
NCT02974504 -
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
|
Phase 4 | |
| Completed |
NCT05053828 -
Type 2 Diabetes With Antiplatelet Drugs
|
||
| Not yet recruiting |
NCT03659383 -
The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine
|
Phase 4 | |
| Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
| Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
| Completed |
NCT03979768 -
Risk Assessment of Type 2 Diabetes in Pharmacies
|
N/A | |
| Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
| Active, not recruiting |
NCT04994288 -
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT03290768 -
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
|
N/A | |
| Enrolling by invitation |
NCT04088851 -
"The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"
|
N/A | |
| Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|
||
| Active, not recruiting |
NCT04451837 -
Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
|
Phase 2 |